Otsuka Corp represents a strong set of values and a unique corporate philosophy. The company is committed to creating innovative products and services that contribute to the well-being of people worldwide. With a focus on the three values of integrity, perseverance, and entrepreneurship, Otsuka Corp strives to make a positive impact within society. By combining their expertise in various fields, the company aims to tackle global healthcare challenges and fulfill their corporate mission of improving the health and happiness of people globally. Otsuka Corp's dedication to continuous innovation and social responsibility showcases their commitment to creating a better future for all.

Otsuka Corp is primarily present in Japan, where it is headquartered. The company has a strong presence in many other countries and regions as well, including the United States, China, Europe, and Southeast Asia. With its global reach and diverse operations, Otsuka Corp continues to expand its footprint and deliver its innovative products and services to customers around the world.

Otsuka Corp has achieved several significant milestones throughout its history. One noteworthy achievement is the introduction of its flagship product, Pocari Sweat, a popular electrolyte drink that has gained widespread recognition and success in the market. Additionally, the company has successfully expanded its global presence with various subsidiaries and strategic collaborations, enabling it to penetrate international markets more effectively. Otsuka Corp has also made significant advancements in the pharmaceutical industry, particularly in mental health research and development. Notably, the company introduced Abilify, a widely used medication for treating schizophrenia and bipolar disorder. The continuous dedication to innovation and strategic growth has established Otsuka Corp as a leading player in the global market.

Otsuka Corp, a renowned Japanese company, has a rich history and background. Established in 1964, Otsuka Corp has been dedicated to enhancing the health and well-being of people through its diverse range of products and services. The company focuses on pharmaceuticals, nutraceuticals, and consumer products, all aimed at meeting the evolving needs of individuals worldwide. Otsuka Corp's commitment to innovation and breakthrough technologies has led to the development of groundbreaking treatments in areas such as mental health, oncology, and nephrology. With its extensive global presence, Otsuka Corp strives to make a positive impact on society by improving healthcare and contributing to the betterment of people's lives.

The main competitors of Otsuka Corp in the market are multinational pharmaceutical companies such as Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., and Eisai Co., Ltd. These rivals operate in similar sectors and offer a wide range of healthcare products and services. Otsuka Corp competes with these companies in terms of research and development, product innovation, market presence, and global reach. Despite the fierce competition, Otsuka Corp has established itself as a renowned player in the industry, focusing on areas like pharmaceuticals, nutraceuticals, and medical devices.

Otsuka Corp is primarily active in the pharmaceutical and healthcare industries.

The business model of Otsuka Corp revolves around healthcare and consumer products. As a multinational company, Otsuka Corp focuses on developing innovative pharmaceuticals and nutraceuticals, along with providing related healthcare services. They aim to improve the quality of life by addressing various medical needs and delivering reliable solutions. Otsuka Corp is committed to research and development, manufacturing, and marketing of products that cater to mental health, oncology, gastroenterology, and nephrology, among other therapeutic areas. Through their diverse portfolio and strategic partnerships, Otsuka Corp aims to contribute to the well-being of individuals worldwide.

Det Otsuka P/E-forhold er 25,14.

Otsuka KUV er 1,18.

AlleAktien Kvalitetsscore for Otsuka er 8/10.

Den forventede Otsuka omsætning er 1,07 Bio. JPY.

Den forventede Otsuka indtjening er 50,24 mia. JPY.

Otsuka Corp is a Japanese company that operates in various business fields. The company specializes in pharmaceuticals, nutrition, cosmetics, and beverages and operates worldwide. It is considered a global player in the industry with approximately 47,000 employees. In the pharmaceutical sector, Otsuka develops and produces innovative medications for various diseases such as neurology, oncology, cardiology, and psychiatry. Some examples include Abilify, an antipsychotic medication for schizophrenia and bipolar disorders, and Rexulti, a medication for the treatment of depression and schizophrenia. Another well-known product is the gastrointestinal medication Pletal, used for impaired blood flow. In the nutrition sector, Otsuka offers dietary supplements suitable for athletes and general use. This includes products like Pocari Sweat, a beverage containing electrolytes to prevent fluid loss during physical activity. Another product is Calorie Mate, a meal replacement supplement. Additionally, Otsuka is active in the cosmetics industry and offers numerous skincare products. Some of the notable products include the Oronine H Ointment line, which aims to help with skin conditions, injuries, and burns, and the Skin Aqua line, which serves as sun protection products. In the beverage sector, Otsuka offers natural juices and teas distributed in Japan and other countries. Otsuka Corp emphasizes intensive research and development in the development of its products. To achieve this goal, the company collaborates with renowned universities and research institutions worldwide. To ensure the quality of its products, Otsuka adheres to strict quality standards that ensure responsible practices with regard to human beings and the environment. As a globally oriented company, Otsuka is continually striving to adapt its products and services to meet the needs of its customers. To achieve this, the company works closely with local partners and experts. Overall, Otsuka's business model is characterized by intensive research and development, high-quality standards, and a wide range of products in different business sectors. The company specializes in developing innovative products that provide high value to customers. Responsible corporate governance is a key focus.

Otsuka udbetaler et udbytte på 125,00 JPY fordelt over 1 udbetalinger om året.

Otsuka udbetaler 1 gange om året en udbytte.

ISIN'en for Otsuka er JP3188200004.

WKN for Otsuka er 502503.

Tickeren for Otsuka er 4768.T.

I løbet af de sidste 12 måneder betalte Otsuka en dividende på 135,00 JPY . Dette svarer til et dividendeudbytte på omkring 4,05 %. For de kommende 12 måneder vil Otsuka sandsynligvis betale en dividende på 138,55 JPY.

Udbytteafkastet for Otsuka er i øjeblikket 4,05 %.

Otsuka betaler kvartalsvis udbytte. Dette uddeles i månederne januar, januar, januar, januar.

Otsuka betalte udbytte hvert år i løbet af de sidste 23 år.

For de kommende 12 måneder forventes der dividender på 138,55 JPY. Dette svarer til et dividendeafkast på 4,16 %.

Otsuka bliver tildelt sektoren 'Informationsteknologi'.

For at modtage det seneste udbytte på Otsuka fra den 1.3.2025 på 70 JPY, skulle du have haft aktien i din portefølje før ex-datoen den 27.12.2024.

Udbetalingen af det sidste udbytte blev foretaget den 1.3.2025.

I løbet af 2023 udbetalte Otsuka 125 JPY i form af dividender.

Udbytterne fra Otsuka udbetales i JPY.